Hjem › Diffust stort B-celle lymfom › Massachusetts › Boston
Diffust stort B-celle lymfom kliniske forsøg i Boston, MA
16 studier for Diffust stort B-celle lymfom søger deltagere på steder i og omkring Boston (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RekruttererFase 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RekruttererFase 1/2
- Dana Farber Cancer Institute, Boston
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
RekruttererFase 3
- Beth Israel Deaconess Medical Center, Boston
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
RekruttererFase 2
- Beth Israel Deaconess Medical Center ( Site 0161), Boston
- Dana Farber Cancer Institute ( Site 0111), Boston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RekruttererFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RekruttererFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RekruttererFase 1/2
- Dana-Farber Cancer Institute ( Site 1013), Boston
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
RekruttererFase 2
- Boston Medical Center, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RekruttererFase 1/2
- Massachusetts General Hospital, Boston
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
RekruttererObservationsstudie
- Dana Farber Cancer Institute, Boston
The CARDIOPROTECT Trial
RekruttererFase 2
- Beth Israel Deaconess Medical Center, Boston
DALY II USA/ MB-CART2019.1 for DLBCL
RekruttererFase 2
- Dana Farber Cancer Institute, Boston
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
RekruttererFase 1
- Dana Farber Cancer Institute, Boston
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RekruttererFase 1
- Massachusetts General Hospital, Boston
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
RekruttererFase 2
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Emapalumab Prevention of CAR-T Cell Associated Toxicities
RekruttererFase 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Diffust stort B-celle lymfom forsøg i andre byer
- New York City, NY21 studier
- Baldwin Park, CA19 studier
- Chicago, IL18 studier
- Houston, TX17 studier
- Los Angeles, CA17 studier
- Milwaukee, WI16 studier
- Nashville, TN15 studier
- Portland, OR15 studier
- Philadelphia, PA15 studier
- Durham, NC14 studier
- Dallas, TX13 studier
- Seattle, WA12 studier
Andre studier i Boston
- Brystkræft111 studier
- Ikke-småcellet lungecancer90 studier
- Kræft (alle typer)86 studier
- Colorektal kræft63 studier
- Metastatisk cancer63 studier
- Lungecancer62 studier
- Ægstockræft61 studier
- Prostatakræft59 studier
- Depression52 studier
- Livmoderslimhindekræft50 studier
- Hjertesvigt44 studier
- Akut myeloid leukæmi44 studier
Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.